Baseline Characteristics of Participants in the ASPREE (ASPirin in Reducing Events in the Elderly) Study

There are no primary prevention trials of aspirin with relevant geriatric outcomes in elderly people. ASPirin in Reducing Events in the Elderly (ASPREE) is a placebo-controlled trial of low-dose aspirin that will determine whether 5 years of daily 100-mg enteric-coated aspirin extends disability-fre...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:The journals of gerontology. Series A, Biological sciences and medical sciences Ročník 72; číslo 11; s. 1586
Hlavní autori: McNeil, John J, Woods, Robyn L, Nelson, Mark R, Murray, Anne M, Reid, Christopher M, Kirpach, Brenda, Storey, Elsdon, Shah, Raj C, Wolfe, Rory S, Tonkin, Andrew M, Newman, Anne B, Williamson, Jeff D, Lockery, Jessica E, Margolis, Karen L, Ernst, Michael E, Abhayaratna, Walter P, Stocks, Nigel, Fitzgerald, Sharyn M, Trevaks, Ruth E, Orchard, Suzanne G, Beilin, Lawrence J, Donnan, Geoffrey A, Gibbs, Peter, Johnston, Colin I, Grimm, Richard H
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: United States 01.11.2017
Predmet:
Activities of Daily Living
Administration, Oral
Aged
Aged, 80 and over
Aging - drug effects
Aspirin - administration & dosage
Australia - epidemiology
Cardiovascular Diseases - epidemiology
Cardiovascular Diseases - prevention & control
Cyclooxygenase Inhibitors - administration & dosage
Dementia - epidemiology
Dementia - prevention & control
Disability Evaluation
Disabled Persons - rehabilitation
Disabled Persons - statistics & numerical data
Dose-Response Relationship, Drug
Double-Blind Method
Female
Humans
Incidence
Male
Prognosis
Quality of Life
United States - epidemiology
Disability
Clinical trial
Primary prevention
Dementia
ISSN:1758-535X, 1758-535X
On-line prístup:Zistit podrobnosti o prístupe
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:There are no primary prevention trials of aspirin with relevant geriatric outcomes in elderly people. ASPirin in Reducing Events in the Elderly (ASPREE) is a placebo-controlled trial of low-dose aspirin that will determine whether 5 years of daily 100-mg enteric-coated aspirin extends disability-free and dementia-free life in a healthy elderly population and whether these benefits outweigh the risks. Set in primary care, this randomized double-blind placebo-controlled trial has a composite primary endpoint of death, incident dementia or persistent physical disability. Participants aged 70+ years (non-minorities) or 65+ years (U.S. minorities) were free of cardiovascular disease, dementia, or physical disability and without a contraindication to, or indication for, aspirin. Baseline data include physical and lifestyle, personal and family medical history, hemoglobin, fasting glucose, creatinine, lipid panel, urinary albumin:creatinine ratio, cognition (3MS, HVLT-R, COWAT, SDMT), mood (CES-D-10), physical function (gait speed, grip strength), Katz activities of daily living and quality of life (SF-12). Recruitment ended in December 2014 with 16,703 Australian and 2,411 U.S. participants, a median age of 74 (range 65-98) years and 56% women. Approximately 55% of the U.S. cohort were from minority groups; 9% of the total cohort. Proportions with hypertension, overweight, and chronic kidney disease were similar to age-matched populations from both countries although lower percentages had diabetes, dyslipidemia, and osteoarthritis. Findings from ASPREE will be generalizable to a healthier older population in both countries and will assess whether the broad benefits of daily low-dose aspirin in prolonging independent life outweigh the risks.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ISSN:1758-535X
1758-535X
DOI:10.1093/gerona/glw342